3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Phase 1/2
1
Status
Terminated
1
Completed
1
Sponsor Class
OTHER
55
INDUSTRY
23
NIH
5
NETWORK
2
Study Type
Interventional
2
Sponsor
Cancer Type
Plasma cell
2
Conditions
Multiple Myeloma
2
Sarcoma, Kaposi
1
Recurrence
1
Genetic Diseases, Inborn
1
Interventions
Dexamethasone
45
Bortezomib
21
Lenalidomide
19
Cyclophosphamide
19
daratumumab
16
Calcium Dobesilate
13
Thalidomide
12
Melphalan
11
carfilzomib
9
Prednisone
7
pomalidomide
6
Peripheral Blood Stem Cell Transplantation
6
Doxorubicin
6
Filgrastim
5
dexamethasone acetate
4
dexamethasone 21-phosphate
4
auricularum
4
Vincristine
4
isatuximab
3
Interferon-alpha
3
Etoposide
3
selinexor
2
sargramostim
2
ixazomib
2
elotuzumab
2
cobimetinib
2
Steroids
2
Radiotherapy
2
Microarray Analysis
2
Granulocyte Colony-Stimulating Factor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
NETWORK
×
Multiple Myeloma
×
ixazomib
×
Clear all
NCT03683277
2025-02-19
IFM2014-01
Intergroupe Francophone du Myelome
Phase 2
Terminated
26 enrolled
NCT03732703
2025-02-14
MyDRUG
Multiple Myeloma Research Consortium
Phase 1/2
Completed
103 enrolled